54 news items
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
MRK
9 May 24
a Prescription Drug User Fee Act (PDUFA), or target action, date of June 21, 2024.
The program also
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
AZN
MRK
MRNA
8 May 24
of the molecular mechanisms underlying cancer cachexia, driving the development of targeted therapies and interventions to manage cachexia symptoms more
Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
ABBV
ATNM
AZN
8 May 24
totaling $750 million. This acquisition aims to bolster Novartis's pipeline with Mariana's advanced cancer-targeting radioligand therapies. Additionally
Ligand Reports First Quarter 2024 Financial Results
AMGN
CASI
JAZZ
7 May 24
accelerated approval to full approval for the treatment of IgAN in the U.S. with a PDUFA target action date of September 5, 2024
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
MRK
29 Apr 24
review with a Prescription Drug User Fee Act (PDUFA), or target action date, of June 17, 2024. V116 is specifically designed to help protect
lc0qj
MRK
25 Apr 24
.
Januvia is one of 10 drugs targeted in ongoing
nmu hth32u5sau7tg13rcxw1qg8pqgqjuoxgcsa5jja1rouz
ATNI
HTZ
MRK
25 Apr 24
coverage on the stock with a Buy rating and announced an $8 price target.
Equities Trading DOWN
jpiqahh5al45up
MRK
25 Apr 24
.
Merck has the following three Prescription Drug User Fee Act (PDUFA), or target action, dates set by the FDA
ch09e82g08mrwsb3n07ju3syhgbpg0x91vsbclxn2rndbjw3eky8im70
ABBV
ATNM
AZN
22 Apr 24
robust through 2024, particularly targeting mid-stage companies with deal values ranging between $1-3 billion. The focus is likely to center on critical
fp9c z1ng5gxqecuh7w6s6q
MRK
19 Apr 24
central review (BICR) using RECIST v1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ
zro9a5xyv9pqtle4no8yre6kg4w zul
ABBV
ATNM
AZN
19 Apr 24
. (NYSE:ATNM), with its groundbreaking advancements in targeted radiotherapies, underscores the burgeoning appeal
o5hk2zqq5fnvxjflswkfwd3b1y5
MRK
18 Apr 24
0
In the assessment of 12-month price targets, analysts unveil insights for Merck & Co, presenting
ew3q9t3a4m0152lkskhnqezeq8191aihahb5s6ecap9wuyb 91rd4
MRK
18 Apr 24
Cantor Fitzgerald analyst Louise Chen reiterates Merck & Co (NYSE:MRK) with a Overweight and maintains $135 price target.
zqlcgrxeu61661ib4ov4mcg7hailn8u0 0nbugkfhz4u9xp8qwwzp5p4zaf
MRK
17 Apr 24
, with a consensus target price of $138.0.
An analyst from Berenberg has decided to maintain their Buy rating on Merck & Co, which
h686dauui7qirpb95h2d8oqxo 01dwiwlq7xx815xo6ze
ADMA
ANIP
MRK
11 Apr 24
believes that the company's vaccine portfolio targets large addressable markets with an estimated total addressable market of around $52
4w9 cxkm89867vvdsa
MRK
PCVX
PFE
10 Apr 24
with a price target of $95.
Market adoption is driven by vaccine coverage, with Prevnar20 currently dominating with a 97% market share
9q6jqj58lgnh favbeo1p4ax
MRK
MRNA
9 Apr 24
, and 8 (36.4%) stable disease at data cutoff.
Sustained de novo T cell induction to targeted neoantigens was seen in 5/5 available patient
vqtupez83maubnaz23t9ixjuoeqt2tpwkk0chi7e51
MRK
8 Apr 24
Berenberg analyst Luisa Hector maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $140 to $143.
gpblc6p0zj6l973wgu77eirt15w7 rfrnl9yhhc8dtowjzy1n05js
MRK
5 Apr 24
Cantor Fitzgerald analyst Louise Chen reiterates Merck & Co (NYSE:MRK) with a Overweight and maintains $135 price target.
eq5f4jxxlfnoo97hzvtt6zvr
MRK
4 Apr 24
decades of research and recognition of the therapeutic importance of targeting KRAS, the development of small